| Trial ID # | NCT04519151 |
| Phase | II |
| Drug Class | Immunotherapy: Checkpoint Inhibitors/PD-1 |
| Drug Name | Pembrolizumab |
| Alternate Drug Names | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 |
| Drugs in Trial | Lenvatinib, Pembrolizumab |
| Eligible Participant | Platinum sensitive high grade serous or endometrioid ovarian cancer |
| Patients Enrolled | 24, median 2 prior therapies (1-2), 50% w/ prior bevacizumab |
| Therapy Setting | Recurrence |
| Study Design | Open-Label, Non-randomized |
| Endpoints | ORR, DCR, DoR, PFS, OS, evaluated per RECIST |
| Efficacy | ORR: 54% (3CR, 10PR) |
| Clinically Significant Adverse Events | Serious AE: |
| Conclusion | The combination of lenvatinib and pembrolizumab shows meaningful responses and manageable toxicity in platinum sensitive recurrent high grade serous OC patients thus potentially provides a non chemotherapy alternative |
| Reference | Bauer S et al. Phase II study of pembrolizumab and lenvatinib in platinum sensitive recurrent ovarian cancer. J Clin Oncol 42, 2024 (suppl 16; abstr 5581) Bauer S et al. Poster |